News - North America, Forest Laboratories

Filter

Popular Filters

Forest debuts MMD drug Fetzima in US pharmacies

19-12-2013

US drugmaker Forest Laboratories says that Fetzima (levomilnacipran ER capsules) is now available in…

FetzimaForest LaboratoriesMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPierre FabreUSA

Forest spends $240 million for US rights to Saphris; streamlines operations

02-12-2013

US drugmaker Forest Laboratories is acquiring exclusive rights in the USA for Saphris (asenapine) sublingual…

FinancialForest LaboratoriesLicensingMerck & CoNeurologicalNorth AmericaPharmaceuticalSaphrisUSA

FDA calls for more info from Forest and Gedeon Richter on cariprazine

21-11-2013

The US Food and Drug Administration has issued a complete response letter regarding the New Drug Application…

cariprazineForest LaboratoriesGedeon RichterNeurologicalNorth AmericaPharmaceuticalRegulation

Forest Labs settles Bystolic litigation with Actavis

07-11-2013

US drugmaker Forest Laboratories has entered into a settlement agreement with generics drug major Actavis…

ActavisBystolicCardio-vascularForest LaboratoriesGenericsLegalNorth AmericaPatents

Forest Labs reports rise in sales and EPS doubles in second quarter results

23-10-2013

Forest Laboratories has released its second quarter results which showed that net sales for the quarter…

BystolicCNS DiseasesDalirespFinancialForest LaboratoriesLinzessNamendaNorth AmericaPharmaceuticalRespiratory and PulmonarySavellaTeflaroTudorza PressairViibryd

Forest Labs names new CEO to replace Howard Solomon

11-09-2013

US drugmaker Forest Laboratories (NYSE: FRX) saw its shares rise 2.5% to $44.50 yesterday (September…

BoardroomFinancialForest LaboratoriesNorth AmericaPharmaceutical

Forest Labs and Almirall opt to delay US filing for combo COPD drug

15-08-2013

USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Amerigen collaborates with Forest Labs

01-08-2013

US generics drugmaker Amerigen Pharmaceuticals has entered into a collaboration agreement with Forest…

Amerigen PharmaceuticalsForest LaboratoriesGenericsNorth AmericaProduction

Forest Labs and Fabre's MMD drug gains FDA approval

26-07-2013

US drugmaker Forest Laboratories (NYSE: FRX) and France-based independent Pierre Fabre Laboratories have…

FetzimaForest LaboratorieslevomilnacipranNeurologicalNorth AmericaPharmaceuticalPierre FabreRegulation

Forest agrees another license deal for Bystolic

22-07-2013

US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Insights on the US Alzheimer's disease market

03-12-2012

The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

FDA nod for use of Ironwood and Forest's Linzess in certain cases of IBS and constipation

03-09-2012

The US Food and Drug Administration last week approved Linzess (linaclotide), co-marketed by US drugmakers…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideLinzessNorth AmericaPharmaceuticalRegulation

US FDA backs Forest and Almirall's Tudorza Pressair to treat COPD

24-07-2012

US drugmaker Forest Laboratories (NYSE: FRX) and Spain's largest pharma firm Almirall (ALM: MC,) which…

AlmirallForest LaboratoriesNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

FDA extends review of Ironwood and Forest's linaclotide to September

24-04-2012

The US Food and Drug Administration has told USA-based drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD)…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulation

Forest Labs buys Bystolic rights from Janssen for $357 million

03-04-2012

Forest Laboratories, (NYSE: FRX) says it has acquired all US patents and other US and Canadian intellectual…

BystolicCardio-vascularForest LaboratoriesJanssen PharmaceuticaJohnson & JohnsonLicensingNorth AmericaPharmaceuticalSavella

US FDA delays approval of Almirall and Forest Laboratories' COPD drug

30-03-2012

The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Forest files suit over Bystolic patent; generic Lexapro launched in USA

15-03-2012

US drugmaker Forest Laboratories (NYSE: FRX) and Janssen Pharmaceutica, a unit of health care giant Johnson…

BystolicCardio-vascularForest LaboratoriesGenericsJanssen PharmaceuticaJohnson & JohnsonLexaproNeurologicalNorth AmericaPatentsRegulationTeva Pharmaceutical IndustriesWatson Pharmaceuticals

US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall

24-10-2011

US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) said yesterday…

AlmirallForest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulationResearch

Majority of US surveyed MCOs will consider reimbursing novel OPAT agents; report

17-08-2011

According to surveyed physicians in the USA, the use of out-patient parenteral antibiotic therapy (OPAT)…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsForest LaboratoriesIvanzMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalTeflaroTheravanceVibativ

FDA filings for Ironwood and Forest for linaclotide, and GSK and XenoPort for Horizant ER

10-08-2011

US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) have submitted…

Forest LaboratoriesGastro-intestinalsGlaxoSmithKlineHorizantIronwood PharmaceuticalslinaclotideNeurologicalNorth AmericaPharmaceuticalRegulationXenoPort

Moves to bar Forest CEO from US health care contracts dropped by HHS-OIG

08-08-2011

week of high-profile activity for US drugmaker Forest Laboratories (NYSE: FRX), there was welcome news…

Forest LaboratoriesLegalManagementNorth AmericaPharmaceutical

Back to top